Peregrine to Report Third Quarter Fiscal Year 2013 Financial Results After Market Close on March 12, 2013

[at noodls] – TUSTIN, CA — (Marketwire) — 03/05/13 — Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment … more

View todays social media effects on PPHM

View the latest stocks trending across Twitter. Click to view dashboard

See who Peregrine is hiring next, click here to view